Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViSion Serenity: Vamifeport (VIT-2763) in sickle cell disease
2020-005072-34Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamifeport in sickle cell disease (SCD) (3 arms), sponsored by CSL Vifor. Primary endpoint: Change in indirect bilirubin at 8 weeks. Started Jun 2021; status: completed.
02
Drugs
vamifeport
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2020-005072-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005072-34.